Biotech stocks ready for more Covid-19 results in first quarter

The benchmark Nasdaq Biotech Index has climbed 26% this year, compared with a 15% gain in the S&P 500 Index, pointing to no let-up in market-moving drug trial data even during the pandemic.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app